Skip to Content

IACS Leadership

Senior Associate Director, Drug Discovery

Jannik Andersen, Ph.D.

Jannik Andersen, Ph.D., has extensive expertise in basic and translational cancer research, oncogenic  signaling and targeted oncology therapeutics. Prior to joining MD Anderson, he was the associate director of drug discovery at the Belfer Institute of Applied Cancer Science at Dana-Farber Cancer Institute, where he served as the science alliance manager for the corporate partnership with Merck & Co., Inc. Prior to joining the Belfer Institute, he worked for Merck Research Laboratories, where he led early drug discovery programs providing genetic target validation and pharmacological evaluation of lead molecules.  

Andersen has authored highly cited original articles and reviews in drug discovery, signal transduction and personalized molecular oncology published in Cell, Nature, Nature Medicine and Science Translational Medicine. He is the principal author of a peer-reviewed website on protein tyrosine phosphatases (PTPs) focusing on sequence analysis, genomics, protein structure and inhibitor design. This original work led to the commercialization of the Expression Arrest™ shRNA library sold by Open Biosystems (RNAi screening).  

Andersen has a multidisciplinary educational background with a M.Sc. in chemical engineering from the Technical University of Denmark, as well as a M.Sc. degree in human biology from the University of Copenhagen and a Ph.D. from the Faculty of Medicine, University of Copenhagen, Denmark. He conducted his Ph.D. educational research at Novo Nordisk, training in a world-class signal transduction laboratory focusing on protein phosphatase small molecule drug discovery.  Dr. Andersen conducted his post‐doctoral studies in the laboratory of Nicholas Tonks, Ph.D., Cold Spring Harbor Laboratory, N.Y.


© 2014 The University of Texas MD Anderson Cancer Center